Aclaris Therapeutics, Inc. Earnings Per Share (Diluted)
Aclaris Therapeutics, Inc. (ACRS) reported Earnings Per Share (Diluted) of -$0.15 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Aclaris Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.15.
- Aclaris Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.15.
- Aclaris Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.16.
- Aclaris Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.12.
- Aclaris Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$0.53.
- Aclaris Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$1.71.
- Aclaris Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$1.27.
- Aclaris Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$1.33.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.15 10-Q · filed 2026-08-06 | -$0.30 10-Q · filed 2026-08-06 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.15 10-Q · filed 2026-05-07 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.53 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.12 10-Q · filed 2025-11-06 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.37 10-Q · filed 2025-11-06 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.13 10-Q · filed 2026-08-06 | -$0.25 10-Q · filed 2026-08-06 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.12 10-Q · filed 2026-05-07 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.24 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.71 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.11 10-Q · filed 2025-11-06 | -$0.26 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.50 10-Q · filed 2025-11-06 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-06-30 | -$0.15 10-Q · filed 2025-08-07 | -$0.39 10-Q · filed 2025-08-07 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-03-31 | -$0.24 10-Q · filed 2025-05-08 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-12-31 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.27 10-K · filed 2025-02-27 |
| 2023-09-30 | -$0.41 10-Q · filed 2024-11-06 | -$0.83 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.25 10-Q · filed 2024-11-06 | -$1.67 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.42 10-Q · filed 2024-08-07 | -$0.84 10-Q · filed 2024-08-07 | -$1.25 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.56 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-03-31 | -$0.42 10-Q · filed 2024-05-07 | -$0.84 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.13 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.45 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2022-12-31 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.71 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.03 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.33 10-K · filed 2024-02-27 |
| 2022-09-30 | -$0.30 10-Q · filed 2023-11-06 | -$0.61 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$0.92 10-Q · filed 2023-11-06 | -$1.29 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-06-30 | -$0.31 10-Q · filed 2023-08-07 | -$0.62 10-Q · filed 2023-08-07 | -$0.99 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-03-31 | -$0.31 10-Q · filed 2023-05-08 | -$0.68 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.02 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.36 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.72 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.06 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.60 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.35 10-Q · filed 2022-11-08 | -$0.68 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.23 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.34 10-Q · filed 2022-08-03 | -$0.90 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | -$0.57 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$1.20 10-K · filed 2023-02-23 | |||
| 2019-12-31 | -$3.90 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |